FEATURED SPEAKER: Mesenchymal Stem Cell Treatment for ASDs: The Therapeutic Rational and its Future Potential
Following the Witebsky-Rose criteria, we aim to test the hypothesis of ASD as an autoimmune disease. Evidence for the presence of specific immune markers, and the presence of a family history of autoimmune diseases, points to the possibility of an autoimmune etiology. Due to the potent anti-inflammatory, immunomodulatory and regenerative capacities of mesenchymal stromal stem cells (MSC) and the cumulative clinical experience confirming the safety and efficacy of MSC treatment for various clinical conditions, MSC might open new therapeutic horizons for children with ASD.
Help us help you by joining in Dr. Gesundheit's research efforts by clicking here >>
Benjamin Gesundheit MD, PhD, is a pediatric hematologist oncologist with experience in bone marrow transplantation and experimental cell therapy. He has been affiliated with Hospital for Sick Children at University of Toronto, Hadassah Medical Center, and Hebrew University in Jerusalem. He has lectured and published internationally on topics related to pediatric hematology-oncology, autism, and medical ethics. Currently, he focuses on the potential use of MSC for ASD.